Ginkgo bioworks strengthens end-to-end r&d capabilities in gene therapy through acquisition of stridebio's aav capsid discovery and engineering platform assets

Platform includes large library of existing capsids, which have been optimized for performance and targeting across a range of application areas through validation in large animal models the addition of stridebio's structure-guided aav engineering capabilities combined with ginkgo's already extensive assets make ginkgo a unique one-stop shop capable of providing r&d services for gene therapy manufacturing across capsid, payload, and cell line optimization as part of the transaction, ginkgo also receives ip and data for stridebio's lead preclinical asset for arrhythmogenic right ventricular cardiomyopathy, a rare genetic heart disease, which ginkgo plans to sell or outlicense to a commercial partner boston , april 5, 2023 /prnewswire/ -- ginkgo bioworks (nyse: dna), which is building the leading platform for cell programming and biosecurity, today announced the acquisition of stridebio's adeno-associated virus (aav) capsid discovery and engineering platform assets with a secondary close scheduled upon the transfer of certain additional in-license agreements to ginkgo. ginkgo will incorporate these capabilities and ip into its end-to-end aav gene therapy development platform, allowing ginkgo's customers to leverage new tools to effectively target many different tissue types, and potentially to improve the safety profile of their future gene therapies.
DNA Ratings Summary
DNA Quant Ranking